Project 3: Synthesis and Optimization of Selective a4B2 nAChR Desensitizers According to the United States National Institute on Drug Abuse, abuse and addiction to alcohol, nicotine, and illegal substances cost Americans upwards of half a trillion dollars a year, considering their combined medical, economic, criminal, and social impact. Every year, abuse of illicit drugs and alcohol contributes to the death of more than 100,000 Americans, while tobacco is linked to an estimated 440,000 deaths per year. With this in mind, there is a great need to develop new therapeutics for drug abuse and addictions. In this grant we will use medicinal chemistry to design, synthesize and optimize desensitizers of a4B2 nAChR based structure activity relationships for Sazetidine A analogues. In this application, we present a new class of a4B2 desensitizers called Triazetidines and propose the optimization both in vitro and in vivo. We will also provide gram scale synthetic support for all optimized candidates in vivo behavioral evaluation (project 2) and acute toxicity studies (project 3). This will allow us to establish a therapeutic index for the candidate compounds in this proposal.
Tobacco use and nicotine addiction are an immense public health problem, and the health costs associated with smoking are estimated as $75 billion per year in the U.S. Current treatments for nicotine addiction are not adequate. The goal of this NCDDDG is to develop smoking cessation drugs to help the nearly 50 million people in N. America and 1 billion people worldwide end their addiction to nicotine and stop smoking.
|Hussmann, G Patrick; DeDominicis, Kristen E; Turner, Jill R et al. (2014) Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain. J Neurochem 129:721-31|
|Burke, Dennis A; Heshmati, Pooneh; Kholdebarin, Ehsan et al. (2014) Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats. Eur J Pharmacol 741:132-9|
|Liu, Yong; Paige, Mikell; Olson, Thao T et al. (2014) Synthesis and pharmacological characterization of new neuronal nicotinic acetylcholine receptor ligands derived from Sazetidine-A. Bioorg Med Chem Lett 24:2954-6|
|Levin, Edward D (2013) Complex relationships of nicotinic receptor actions and cognitive functions. Biochem Pharmacol 86:1145-52|
|Levin, Edward D; Cauley, Marty; Rezvani, Amir H (2013) Improvement of attentional function with antagonism of nicotinic receptors in female rats. Eur J Pharmacol 702:269-74|
|Levin, Edward D; Sexton, Hannah G; Gordon, Karen et al. (2013) Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor *2-/- and *7-/- mice. Eur J Pharmacol 718:167-72|
|Rezvani, Amir H; Cauley, Marty; Xiao, Yingxian et al. (2013) Effects of chronic sazetidine-A, a selective ?4?2 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats. Psychopharmacology (Berl) 226:35-43|
|Liu, Yong; Richardson, Janell; Tran, Thao et al. (2013) Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective ýý4ýý2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. J Med Chem 56:3000-11|
|Rezvani, Amir H; Timofeeva, Olga; Sexton, Hannah G et al. (2012) Effects of sazetidine-A, a selective ?4?2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats. Eur J Pharmacol 682:110-7|
|Rezvani, Amir H; Cauley, Marty; Sexton, Hannah et al. (2011) Sazetidine-A, a selective ?4?2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) 215:621-30|